Former CEO & Co-Founder
Jack Syage, Ph.D. has over 30 years of experience in creating and leading the development of innovative technologies in medical and analytical instrumentation. He is regarded as a leading expert in mass spectrometry and trace chemical detection and is in the top 1% of cited scientists—appearing on the list of Most Highly Cited Chemists—with over 140 publications and more than 30 U.S. patents issued or pending. Jack served as CEO and co-founder of ImmunogenX, a global leader in the development of treatments for celiac disease before its combination with Entero Therapeutics. Previously, he founded Syagen Technology and, as CEO, led its growth culminating in its successful acquisition by Safran S.A. Jack is an investor and co-founder of several other companies and currently sits on the boards of directors of Advanced Telesensors, PhageTech, Analytical Detection and Appellation Ventures. Jack earned his B.A. and Ph.D. from Hamilton College and Brown University, respectively, where he won several academic awards including Best Thesis. He received a Tibbets Award from SBIR in 2020.